LCM
LENZ

Laurion Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Laurion Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,743
Closed -$31.7K – 706
2023
Q2 		$31.7K Sell
1,743
-70,128
-98% -$1.4M ﹤0.01% 574
2023
Q1 		$1.23M Sell
71,871
-10,072
-12% -$163K 0.01% 296
2022
Q4 		$1.9M Hold
81,943
– – 0.01% 311
2022
Q3 		$1.82M Hold
81,943
– – 0.01% 336
2022
Q2 		$1.58M Buy
+81,943
New +$1.83M 0.02% 248

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laurion Capital Management's LENZ Position: Q3 2023 in Review

Laurion Capital Management sold out of LENZ Therapeutics (LENZ) in Q3 2023, closing a stake of 1,743 shares — an estimated $31.7K sold.

Laurion Capital Management first reported a position in LENZ in Q2 2022 and held it in 5 quarters. The position peaked at $1.9M in Q4 2022. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • Laurion Capital Management reported no remaining LENZ Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 1,743 LENZ Therapeutics shares in Q3 2023, an estimated $31.7K.
  • Laurion Capital Management first reported a position in LENZ Therapeutics in Q2 2022 and held it in 5 quarters.
  • Laurion Capital Management's LENZ Therapeutics position peaked at $1.9M in Q4 2022.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.